Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Jan 29, 2026
- Closes
- Nov 9, 2026 (in 25 days)
Similar opportunities open now
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Nov 2029Up to $600K
- Diabetes Research Centers (P30 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2027Up to $1M
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Mar 2027Up to $500K
Classification and identifiers
- Solicitation number
- RFA-DK-27-112
- Assistance listing (CFDA)
- 93.847
Amount
Amount not listed here. Check the official program.
Who can apply
Private colleges and universities and Public colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.
This is a Forecast for a single source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
About this opportunity
The primary purpose of this FOA is to support the EDIC Research Center in continuing long-term follow-up of the EDIC cohort to study the development and progression of complications in type 1 diabetes (T1D). The research will address severe microvascular disease, cardiovascular and liver disease, sleep disorders, mortality, and other comorbidities. The goals are to investigate the trajectory of age-related morbidities such as cognition, physical function, and frailty, and to identify their associations with risk factors that affect quality of life, self-management, and caregiver burden. Particular emphasis will be placed on evaluating the impact of emerging therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, on renal and cardiovascular outcomes. The initiative also encourage...